Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home News

Sanders blasted after blocking bipartisan kids’ cancer research bill: ‘Grinch,’ ‘selfish’

admin by admin
December 22, 2025
in News
0
Sanders blasted after blocking bipartisan kids’ cancer research bill: ‘Grinch,’ ‘selfish’
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

A bipartisan bill to bolster research for kids’ cancer drugs was quietly killed on the Senate floor last week, the second year in a row the legislation was torpedoed.

The Mikaela Naylon Give Kids a Chance Act was primed to pass through a fast-track process with near unanimous support in the Senate on Wednesday, save for one lawmaker who sought to amend the bill: Sen. Bernie Sanders, I-Vt.

‘What’s happened right here in front of us? The Grinch is stealing kids’ lives, and they’re stealing hope from the families, hope from the families that might have an opportunity just to try for a political agenda,’ said Sen. Markwayne Mullin, R-Okla., who brought the bill to the floor.

‘And I hope to God that every single family that’s going through this will hold the senator from Vermont accountable, and the state of Vermont will hold him accountable, too, because he’s playing with kids’ lives,’ he continued. ‘He’s literally killing kids in front of us because of his political movement, and it is ridiculous.’

Sanders’ move to block the bill was not a surprise. Several lawmakers who spoke in favor of the legislation urged him not to go through with the decision as pediatric cancer research advocates looked on from the viewing gallery. But doing so once again sets the bill back to square one as Congress enters a new year.

The Vermont independent explained that he had no problem with the legislation, which would have incentivized the Food and Drug Administration (FDA) and drug companies to encourage more relevant pediatric studies and invest in rare pediatric disease treatments, but he wanted to tack on an amendment to fund community health centers throughout the country.

‘This is not a radical amendment,’ Sanders said. ‘I’m not coming here saying, ‘Let’s do something we’ve not talked about.’ I’m not talking about passing Medicare for all here. I am talking about doing what the Republicans and Democrats agreed to a year ago but was torpedoed by some tweets from Elon Musk.’

Lawmakers already had a version of the bill teed up for passage last year, attached to the colossal, year-end temporary funding extension produced by the House.

But that package was ultimately blown apart by tech billionaire Elon Musk, who at the time was coming to Washington, D.C., to serve as President Donald Trump’s government waste attack dog at the Department of Government Efficiency (DOGE).

What eventually passed in late 2024 was a slimmed-down, three-month extension to government funding without the pediatric cancer research bill, and several other policy and funding riders eyed by both sides of the aisle.

Lawmakers who spoke in support of Mullin’s bill argued that they supported Sanders’ desire to fund community health centers, but the underlying legislation was too important to let die on the vine again.

Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy, R-La., said he shared the concern for increased funding for health centers and committed to doing so when Congress returned, but that the ‘irony here is that the objection is going to come out of a genuine concern that people achieve healthcare.’

‘But there’s no one way to treat the ills, literally, the ills of the United States of America, and to think that we can do it all at once, it’s just not true,’ Cassidy said. ‘But also to say that you’re not going to give a chance for children to have a cure for cancer if you don’t get what you want, it’s just not true. It is selfish. It is tragic.’

And Sen. Maggie Hassan, D-N.H., shared Sanders’ concern, but noted that the GOP-controlled House had not committed to tackling the issue of community health center funding.

‘As disappointed as I am that the House isn’t ready to support increased funding for community health centers, I also believe that it is important to take action on this package now to help address pediatric cancer and lower prescription drug costs,’ she said. ‘So I am disappointed that this bill will not move forward today.’

This post appeared first on FOX NEWS

Previous Post

Lawsuit claims security cameras sold in the US carried undisclosed surveillance risks

Next Post

Nio stock price analysis as death cross chart pattern nears

Next Post
Nio stock price analysis as death cross chart pattern nears

Nio stock price analysis as death cross chart pattern nears

  • Trending
  • Comments
  • Latest
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
How Companies Use Derivatives To Hedge Risk

How Companies Use Derivatives To Hedge Risk

February 19, 2025
How crazy popcorn buckets became big business for movie theaters

How crazy popcorn buckets became big business for movie theaters

February 19, 2025
Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

0
Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

0
Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

0
How crazy popcorn buckets became big business for movie theaters

How crazy popcorn buckets became big business for movie theaters

0
Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

December 24, 2025
GLP-1 weight-loss pills set to reshape US food demand in 2026

GLP-1 weight-loss pills set to reshape US food demand in 2026

December 24, 2025
US stocks hold steady on Christmas Eve as investors watch Santa Claus rally

US stocks hold steady on Christmas Eve as investors watch Santa Claus rally

December 24, 2025
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

December 24, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

    Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

    December 24, 2025
    GLP-1 weight-loss pills set to reshape US food demand in 2026

    GLP-1 weight-loss pills set to reshape US food demand in 2026

    December 24, 2025
    US stocks hold steady on Christmas Eve as investors watch Santa Claus rally

    US stocks hold steady on Christmas Eve as investors watch Santa Claus rally

    December 24, 2025
    Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

    Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

    December 24, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved